Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 305–312 | Cite as

Resveratrol Improves Survival and Prolongs Life Following Hemorrhagic Shock

  • Ahmar Ayub
  • Ninu Poulose
  • Raghavan Raju
Research Article

Abstract

Resveratrol has been shown to potentiate mitochondrial function and extend longevity; however, there is no evidence to support whether resveratrol can improve survival or prolong life following hemorrhagic shock. We sought to determine whether (a) resveratrol can improve survival following hemorrhage and resuscitation and (b) prolong life in the absence of resuscitation. Using a hemorrhagic injury (HI) model in the rat, we describe for the first time that the naturally occurring small molecule, resveratrol, may be an effective adjunct to resuscitation fluid. In a series of three sets of experiments we show that resveratrol administration during resuscitation improves survival following HI (p < 0.05), resveratrol and its synthetic mimic SRT1720 can significantly prolong life in the absence of resuscitation fluid (<30 min versus up to 4 h; p < 0.05), and resveratrol as well as SRT1720 restores left ventricular function following HI. We also found significant changes in the expression level of mitochondria-related transcription factors Ppar-α and Tfam, as well as Pgc-1α in the left ventricular tissues of rats subjected to HI and treated with resveratrol. The results indicate that resveratrol is a strong candidate adjunct to resuscitation following severe hemorrhage.

Notes

Acknowledgments

RR acknowledges financial support from the National Institute of General Medical Sciences (R01 GM 101927) and laboratory startup assistance from the Georgia Regents University, Augusta, Georgia, United States of America.

Supplementary material

10020_2015_2101305_MOESM1_ESM.pdf (460 kb)
Supplementary material, approximately 459 KB.

References

  1. 1.
    Minino AM, Anderson RN, Fingerhut LA, Boudreault MA, Warner M. (2006) Deaths: injuries, 2002. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 54:1–124.Google Scholar
  2. 2.
    Spinella PC, Holcomb JB. (2009) Resuscitation and transfusion principles for traumatic hemorrhagic shock. Blood Rev. 23:231–40.CrossRefGoogle Scholar
  3. 3.
    Kauvar DS, Lefering R, Wade CE. (2006) Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J. Trauma. 60:S3–11.CrossRefGoogle Scholar
  4. 4.
    Curry N, et al. (2011) The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit. Care. 15:R92.CrossRefGoogle Scholar
  5. 5.
    Magnotti LJ, et al. (2011) Improved survival after hemostatic resuscitation: does the emperor have no clothes? J. Trauma. 70:97–102.CrossRefGoogle Scholar
  6. 6.
    McSwain NE, et al. (2011) State of the art of fluid resuscitation 2010: prehospital and immediate transition to the hospital. J. Trauma. 70:S2–10.CrossRefGoogle Scholar
  7. 7.
    Poulose N, Raju R. (2014) Aging and injury: alterations in cellular energetics and organ function. Aging Dis. 5:101–8.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Raju R, Bland KI, Chaudry IH. (2008) Estrogen: a novel therapeutic adjunct for the treatment of trauma-hemorrhage-induced immunological alterations. Mol. Med. 14:213–21.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Thacker SA, Robinson P, Abel A, Tweardy DJ. (2013) Modulation of the unfolded protein response during hepatocyte and cardiomyocyte apoptosis in trauma/hemorrhagic shock. Sci. Rep. 3:1187.CrossRefGoogle Scholar
  10. 10.
    Hierholzer C, et al. (1998) Interleukin-6 production in hemorrhagic shock is accompanied by neutrophil recruitment and lung injury. Am. J. Physiol. 275:L611–621.PubMedGoogle Scholar
  11. 11.
    Villarroel JP, et al. (2013) Hemorrhagic shock and resuscitation are associated with peripheral blood mononuclear cell mitochondrial dysfunction and immunosuppression. J. Trauma Acute Care Surg. 75:24–31.CrossRefGoogle Scholar
  12. 12.
    Fishman JE, et al. (2013) Oxidative modification of the intestinal mucus layer is a critical but unrecognized component of trauma hemorrhagic shock-induced gut barrier failure. Am. J. Physiol. Gastrointest. Liver Physiol. 304:G57–63.CrossRefGoogle Scholar
  13. 13.
    Hsieh CH, et al. (2009) Trauma-hemorrhage and hypoxia differentially influence kupffer cell phagocytic capacity: role of hypoxia-inducible-factor-1alpha and phosphoinositide 3-kinase/Akt activation. Ann. Surg. 250:995–1001.CrossRefGoogle Scholar
  14. 14.
    Kan WH, et al. (2008) Flutamide protects against trauma-hemorrhage-induced liver injury via attenuation of the inflammatory response, oxidative stress, and apoptosis. J. Appl. Physiol. (1985)} 105:595–602.CrossRefGoogle Scholar
  15. 15.
    Sawant DA, Tharakan B, Hunter FA, Childs EW. (2014) The role of intrinsic apoptotic signaling in hemorrhagic shock-induced microvascular endothelial cell barrier dysfunction. J. Cardiovasc. Transl. Res. 7:711–18.CrossRefGoogle Scholar
  16. 16.
    Escobales N, et al. (2014) Mitochondria-targeted ROS scavenger improves post-ischemic recovery of cardiac function and attenuates mitochondrial abnormalities in aged rats. J. Mol. Cell. Cardiol. 77:136–46.CrossRefGoogle Scholar
  17. 17.
    Schumacker PT, et al. (2014) Mitochondria in lung biology and pathology: more than just a powerhouse. Am. J. Physiol. Lung Cell. Mol. Physiol. 306:L962–74.CrossRefGoogle Scholar
  18. 18.
    Wallace DC. (2011) Bioenergetic origins of complexity and disease. Cold Spring Harb. Symp. Quant. Biol. 76:1–16.CrossRefGoogle Scholar
  19. 19.
    Chen YR, Zweier JL. (2014) Cardiac mitochondria and reactive oxygen species generation. Circ. Res. 114:524–37.CrossRefGoogle Scholar
  20. 20.
    Chen T, et al. (2014) Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via TGF-β/Smad3 pathway. Am. J. Physiol. Heart Circ. Physiol. 308:H424–34.CrossRefGoogle Scholar
  21. 21.
    Catalgol B, Batirel S, Taga Y, Ozer NK. (2012) Resveratrol: French paradox revisited. Front. Pharmacol. 3:141.CrossRefGoogle Scholar
  22. 22.
    Wang R, et al. (2014) Resveratrol protects neurons and the myocardium by reducing oxidative stress and ameliorating mitochondria damage in a cerebral ischemia rat model. Cell. Physiol. Biochem. 34:854–64.CrossRefGoogle Scholar
  23. 23.
    Jian B, Yang S, Chaudry IH, Raju R. (2012) Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1. Mol. Med. 18:209–14.CrossRefGoogle Scholar
  24. 24.
    Wang H, et al. (2014) Resveratrol ameliorates mitochondrial dysfunction but increases the risk of hypoglycemia following hemorrhagic shock. J. Trauma Acute Care Surg. 77:926–933.CrossRefGoogle Scholar
  25. 25.
    Wu CT, Yu HP, Chung CY, Lau YT, Liao SK. (2008) Attenuation of lung inflammation and pro-inflammatory cytokine production by resveratrol following trauma-hemorrhage. Chin. J. Physiol. 51:363–8.PubMedGoogle Scholar
  26. 26.
    Baur JA, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444:337–42.CrossRefGoogle Scholar
  27. 27.
    Price NL, et al. (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15:675–90.CrossRefGoogle Scholar
  28. 28.
    Ferretta A, et al. (2014) Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson’s disease. Biochim. Biophys. Acta. 1842:902–15.CrossRefGoogle Scholar
  29. 29.
    Valero T. (2014) Mitochondrial biogenesis: pharmacological approaches. Curr. Pharm. Des. 20:5507–9.CrossRefGoogle Scholar
  30. 30.
    Tsai YF, Liu FC, Lau YT, Yu HP. (2012) Role of Akt-dependent pathway in resveratrol-mediated cardioprotection after trauma-hemorrhage. J. Surg. Res. 176:171–7.CrossRefGoogle Scholar
  31. 31.
    Sinclair DA, Guarente L. (2014) Small-molecule allosteric activators of sirtuins. Annu. Rev. Pharmacol. Toxicol. 54:363–80.CrossRefGoogle Scholar
  32. 32.
    Park SJ, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 148:421–33.CrossRefGoogle Scholar
  33. 33.
    Sajish M, Schimmel P. (2014) A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature. 519:370–3.CrossRefGoogle Scholar
  34. 34.
    Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. (2012) Are sirtuins viable targets for improving healthspan and lifespan? Nat. Rev. Drug Discov. 11:443–61.CrossRefGoogle Scholar
  35. 35.
    Allard JS, Perez E, Zou S, de Cabo R. (2009) Dietary activators of Sirt1. Mol. Cell. Endocrinol. 299:58–63.CrossRefGoogle Scholar
  36. 36.
    Ba ZF, Chaudry IH. (2008) Role of estrogen receptor subtypes in estrogen-induced organ-specific vasorelaxation after trauma-hemorrhage. Am. J. Physiol. Heart. Circ. Physiol. 295:H2061–7.CrossRefGoogle Scholar
  37. 37.
    Yu HP, Chaudry IH. (2009) The role of estrogen and receptor agonists in maintaining organ function after trauma-hemorrhage. Shock. 31:227–37.CrossRefGoogle Scholar
  38. 38.
    Gano LB, et al. (2014) The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice. Am. J. Physiol. Heart. Circ. Physiol. 307:H1754–63.CrossRefGoogle Scholar
  39. 39.
    Mitchell SJ, et al. (2014) The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. 6:836–43.CrossRefGoogle Scholar
  40. 40.
    Yang SH, et al. (2014) Cardioprotection by estrogen related receptor (ERR)-beta and -gamma agonist DY131 after trauma-hemorrhage (T-H) is via DY131-derived restoration of cardiac sirtuins (SIRT) [Abstract]. Shock. 41 Suppl 2:63–4.Google Scholar
  41. 41.
    Kentner R, et al. (2002) Early antioxidant therapy with Tempol during hemorrhagic shock increases survival in rats. J. Trauma. 53:968–77.CrossRefGoogle Scholar
  42. 42.
    Gazmuri RJ, Radhakrishnan J. (2012) Protecting mitochondrial bioenergetic function during resuscitation from cardiac arrest. Crit. Care Clin. 28:245–270.CrossRefGoogle Scholar
  43. 43.
    Szabo C, Modis K. (2010) Pathophysiological roles of peroxynitrite in circulatory shock. Shock. 34 Suppl 1:4–14.CrossRefGoogle Scholar
  44. 44.
    Powell RD, et al. (2015) MitoQ modulates oxidative stress and decreases inflammation following hemorrhage. J. Trauma Acute Care Surg. 78:573–9.CrossRefGoogle Scholar
  45. 45.
    Shen Q, et al. (2014) Ubiquinol decreases hemorrhagic shock/resuscitation-induced microvascular inflammation in rat mesenteric microcirculation. Physiol. Rep. 2.pii:e12199.CrossRefGoogle Scholar
  46. 46.
    Li H, Horke S, Forstermann U. (2013) Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol. Sci. 34:313–9.CrossRefGoogle Scholar
  47. 47.
    Juan SH, Cheng TH, Lin HC, Chu YL, Lee WS. (2005) Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem. Pharmacol. 69:41–8.CrossRefGoogle Scholar
  48. 48.
    Carrizzo A, et al. (2013) Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem. Toxicol. 61:215–26.CrossRefGoogle Scholar
  49. 49.
    Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. (2014) Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin. DrugDeliv. 11:1285–98.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  1. 1.Department of Laboratory SciencesGeorgia Regents UniversityAugustaUSA
  2. 2.Department of SurgeryGeorgia Regents UniversityAugustaUSA
  3. 3.Department of Biochemistry and Molecular BiologyGeorgia Regents UniversityAugustaUSA

Personalised recommendations